1119 Lian Pfizer
BioCentury & Getty Images


China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Partnership gives the Perceptive portfolio company commercial infrastructure in China

LianBio’s partnership with Pfizer gives the Perceptive portfolio company a commercial infrastructure in China, and should breathe new life into the pharma’s portfolio in the country.

Nov 20, 2020 | 4:07 AM GMT

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra Yu that can co-develop best-in-class products to freshen its portfolio in the country.

Pfizer Inc. (NYSE:PFE), which participated in LianBio’s $310 million crossover round in October, will contribute up

Read the full 1237 word article

How to gain access

Continue reading with a
two-week free trial.